CVS hikes outlook as Aetna insurance profit rises – Image for illustrative purposes only (Image credits: Pexels)
CVS Health reported first-quarter results that exceeded Wall Street expectations, prompting the company to lift its full-year profit forecast. Revenue climbed to $100.4 billion, a 6.2 percent increase from the prior year, while adjusted earnings per share reached $2.57, topping analyst estimates of $2.20.[1][2] The performance highlighted progress in managing elevated medical costs, particularly within its Aetna insurance unit.
Aetna Drives the Momentum
The Health Care Benefits segment, home to Aetna, posted revenue of nearly $36 billion, up more than 3 percent year over year. Adjusted operating income surged approximately 52.6 percent to $3.04 billion, reflecting over $1 billion in year-over-year improvement.[3] Chief Financial Officer Brian Newman described this as a “substantial improvement” from the prior-year quarter, crediting execution on margin recovery plans.
The medical benefit ratio stood at 84.6 percent, down from 87.3 percent a year earlier and below expectations of around 86.3 percent. Favorable prior-year development in the government business, along with strong medical cost management, contributed to the outperformance. Newman noted better internal forecasting tools and structural changes had enhanced predictability, stating, “We’re improving our capability of forecasting, so the cost trend did not surprise me.”[2][3]
Guidance Receives Upward Revision
CVS raised its 2026 adjusted earnings per share outlook to $7.30 to $7.50, an increase of 30 cents at both ends from the previous range of $7.00 to $7.20. This adjustment represents more than a 4 percent hike at the midpoint. Revenue guidance moved to at least $405 billion, up from $400 billion, while cash flow from operations targets now stand at a minimum of $9.5 billion, previously $9.0 billion.[1][2]
GAAP diluted earnings per share guidance also climbed to $6.24 to $6.44. The revisions stem primarily from strength in Health Care Benefits and Pharmacy & Consumer Wellness segments, though executives maintained caution regarding persistent cost trends and macroeconomic risks. This marks the fifth consecutive quarter of beating expectations.[4]
Performance Across Segments
The Health Services segment, including CVS Caremark, generated revenue exceeding $48 billion, a robust 11 percent rise driven by pharmacy drug mix and brand inflation. Adjusted operating income dipped about 7 percent to roughly $1.5 billion, tempered by client pricing improvements but offset by favorable purchasing economics.
Pharmacy & Consumer Wellness revenue held steady near $32 billion, with same-store sales up around 3 percent on higher prescription volumes that grew over 7 percent. Adjusted operating income fell nearly 9 percent to about $1.2 billion, affected by reimbursement pressures, a milder flu season, and weather-related store closures. Retail pharmacy script share exceeded 29 percent, up from the prior year.[3] Chairman and CEO David Joyner emphasized enterprise-wide execution in serving nearly 185 million people.
Overall adjusted operating income rose more than 12 percent to $5.2 billion, with cash flow from operations at about $4.2 billion.
Implications for Investors and the Industry
Shares of CVS Health rose more than 9 percent in morning trading following the announcement, reflecting investor confidence in the Aetna turnaround. The results add to positive momentum in the health insurance sector, contrasting with challenges faced by some peers amid high Medicare costs. CVS serves a membership of around 26 million in Health Care Benefits, down slightly sequentially, but executives expressed optimism about sustained margin recovery targeting historical levels by 2028.[5][4]
- Key Guidance Updates: Adjusted EPS now $7.30–$7.50 (prior: $7.00–$7.20); Revenue ≥$405B (prior: ≥$400B).
- Aetna Highlights: MLR 84.6%; Op. income +52.6% to $3.04B.
- Enterprise Cash Flow: ≥$9.5B targeted.
For stakeholders, the forecast signals potential for stronger shareholder returns – $850 million returned in the quarter – and continued investment in affordability and access. Yet elevated medical costs in government plans persist, with government payment increases for 2027 falling short of needs, underscoring the need for pricing and benefit adjustments.
As CVS navigates these dynamics, its integrated model positions it to deliver connected care amid industry pressures. The raised outlook underscores a path toward profitability, provided cost management holds firm through the year.
